Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesilate in COVID-19 (SEN-CoV-Fadj)
NCT04390594Phase 3Terminated
- Sponsor
- Institut Pasteur de Dakar
- Start
- Aug 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Standard of Care + Nafamostat mesilate with Standard of Care (2 arms). Primary endpoint: SARS-CoV-2 viral load level at Day 7. Started Aug 2020; status: terminated.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04390594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390594.